TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04345172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sub-Tenon's block with a lacrimal dilator group or a Wescott scissors
Description: Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sub-Tenon's block with a lacrimal dilator group or a Wescott scissors
Description: Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space.
Study: NCT03101137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block with dexmedetomedine
Description: After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal dexamethasone
Description: After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
Study: NCT01282294

Intervention type: DEVICE
Intervention: ETN PROtect
Description: Expert Tibial Nail PROtect with Gentamicin coating
Study: NCT04070937

Intervention type: DIAGNOSTIC_TEST
Intervention: vestibular evoked myogenic potentials
Description: vestibular evoked myogenic potentials to measure the function of otolith organs

Intervention type: DIAGNOSTIC_TEST
Intervention: audiometry
Description: tonal liminar audiometric thresholds

Intervention type: DIAGNOSTIC_TEST
Intervention: audiometry
Description: tonal liminar audiometric thresholds

Intervention type: DIAGNOSTIC_TEST
Intervention: CT and MR imaging of temporal bone
Description: Ct and MR imaging of temporal bone

Intervention type: DIAGNOSTIC_TEST
Intervention: CT and MR imaging of temporal bone
Description: Ct and MR imaging of temporal bone

Intervention type: GENETIC
Intervention: p.P51S mutation
Description: analysis of presence of p.P51S mutation in COCH
Study: NCT01563016

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose drink
Description: participants will receive a drink rich in glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose drink
Description: participants will receive a drink rich in glucose
Study: NCT01655147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
Study: NCT03168360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive rehabilitation
Description: Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Description: Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
Study: NCT00212615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine (Xeloda)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine (Xeloda)
Study: NCT01232153

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: Non invasive ventilation
Study: NCT02623504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: 200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage to match active treatment by mouth twice daily in the morning and in the evening.
Study: NCT03101137

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (bupivacaine)
Description: After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
Study: NCT04070937

Intervention type: GENETIC
Intervention: p.P51S mutation
Description: analysis of presence of p.P51S mutation in COCH
Study: NCT00560950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal 23v polysaccharide vaccine
Description: Duration of Treatment: Single vaccination on Day 1
Study: NCT00056446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatalanib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vatalanib
Study: NCT02905006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will be randomized to receive a combination of injections of Bimekizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will be randomized to receive a combination of injections of Bimekizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will be randomized to receive a combination of injections of Bimekizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will be randomized to receive a combination of injections of Bimekizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will be randomized to receive a combination of injections of Bimekizumab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
Study: NCT00877370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem
Description: One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
Study: NCT00867555

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation
Description: green tea extract TEAVIGO, high in EGCG

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation
Description: green tea extract TEAVIGO, high in EGCG
Study: NCT03331822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Light
Description: high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day\*Light Classic Light will be positioned at each nursing station in the ICU hallway.
Study: NCT01750359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: 500 mg/day for 6 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcumin
Description: 500 mg/day for 6 week
Study: NCT02396394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-Step Adherence Feedback
Description: Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is \<95%.
Study: NCT01883752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed Therapy group
Description: Fluid administration is based on the respiratory variation in the pulse oximeter waveform
Study: NCT02582047

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination with PPV23
Description: GCflu and Pneumovax-23

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination with PCV13
Description: GCflu and Prevenar-13
Study: NCT01751139

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
Study: NCT00490776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
Study: NCT03199391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioWick SureLock Implant
Description: The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
Study: NCT02297555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOBARRIER®
Description: This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
Study: NCT00086099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubincin and Amufostine (Ethyol)
Description: Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubincin
Description: Idarubincin (12mg/m2) and ara-C(N-18)
Study: NCT03591172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Using propolis as a final irrigation in revascularization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano-propolis
Description: Using Nano-propolis as a final irrigation in revasculariztion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: Using saline as a final irrigation in revasculariztion
Study: NCT02785419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm Training with Action Selection
Description: Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
Study: NCT02880527

Intervention type: OTHER
Intervention: Patients with polymyositis / dermatomyositis
Description: recruitment of patients with polymyositis / dermatomyositis using :~1. medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~2. general practitioners~3. the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association
Study: NCT03924921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autogenic training
Description: autogenic training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autogenic training
Description: autogenic training
Study: NCT01566578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinant epidermal growth factor
Description: topical

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Dermal cream without EGF
Study: NCT02506660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone
Description: Dexamethasone in nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perineural saline
Description: Saline in nerve block
Study: NCT03103035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blog
Description: Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
Study: NCT02187315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chrono-chemotherapy pump:Melodie

Intervention type: DEVICE
Group type: OTHER
Intervention: Routine intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chrono-chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin routine-chemotherapy
Study: NCT03551756

Intervention type: OTHER
Intervention: Biomarker Assessment
Description: Exploratory Biomarker Analysis for cardiac patients versus healthy adults

Intervention type: OTHER
Intervention: Biomarker Assessment
Description: Exploratory Biomarker Analysis for cardiac patients versus healthy adults
Study: NCT02618668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine / Propofol Admixture
Description: propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2 mg/kg I.V
Study: NCT02340806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Solis pump (Smiths Medical)
Description: The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Solis pump (Smiths Medical)
Description: The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
Study: NCT01106807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epiduo vehicle gel
Description: 500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epiduo vehicle gel
Description: 500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo vehicle gel
Description: 500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07223
Description: 500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07223
Description: 500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
Description: 500 microliters Epiduo Gel on one of the half-face for the morning dose
Study: NCT02680145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preoperative Pessary Use
Description: Pessary use for 1-4 weeks prior to surgical prolapse repair
Study: NCT00585104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosimendan
Description: 10-minute infusion